Real-World Study Tests Vitamin D’s Impact on Treatment-Free Survival in Early CLL

Chronic lymphocytic leukemia (CLL) is giving researchers an unexpected reason to look more closely at vitamin D. In a large real-world study of people with early-stage CLL, patients who received vitamin D supplements or vitamin D analogs during the disease’s traditional “watch-and-wait” period remained free of leukemia treatment substantially longer than those who did not receive supplementation. The analysis included 5,496 patients treated through Clalit Health Services, Israel’s largest healthcare provider, and found a median treatment-free survival of 147 months among vitamin D users, compared with 82 months among nonusers. The difference was statistically significant, with a reported p value of 0.027. The findings, published in eJHaem, do not prove that vitamin D prevents CLL from progressing, but they provide one of the strongest real-world signals so far that vitamin D status or supplementation may be linked to the pace of the disease.

CLL is the most common form of leukemia in Western countries, but it behaves very differently from patient to patient. Some people live for decades without needing therapy, while others progress more rapidly and require treatment soon after diagnosis. Because early-stage CLL is often asymptomatic and immediate therapy has not been shown to change the disease’s natural history, physicians commonly monitor patients through regular examinations and blood tests. This strategy, known as active surveillance or watch-and-wait, avoids exposing people to treatment-related risks before treatment is necessary. It also creates a distinctive scientific challenge: there are few established interventions that can be tested during this period to delay progression. Supportive care is generally focused on monitoring, managing infections and other complications, and maintaining overall health. The new study therefore addresses a question with potentially broad appeal: whether an inexpensive, widely available nutrient could be associated with a longer period before chemotherapy, targeted therapy or another CLL-directed treatment becomes necessary.

The investigators examined electronic health records from Clalit Health Services covering the period from January 1, 2000, through December 31, 2022. They initially identified 5,505 people who met diagnostic criteria for CLL and had been managed with watch-and-wait for at least three months. Nine patients were not included in the final analysis, leaving 5,496 participants. The median age at diagnosis was 72.2 years, and 55.6 percent were male. Patients were followed from diagnosis until they began their first CLL-directed treatment or were censored from the analysis. Vitamin D exposure was defined relatively stringently: a patient had to receive vitamin D supplementation, a vitamin D analog, or both for at least six months during the watch-and-wait period. In total, 1,862 patients—34 percent of the final cohort—met that definition, while 3,634 did not. The median follow-up from diagnosis to treatment or death was 46 months, although the reported interquartile range extended from 19 to 89 months.

The study’s primary outcome was treatment-free survival, or TFS, a composite measure that counted either the start of CLL therapy or death. The researchers also assessed time to first treatment, known as TTFT, while treating death as a censoring event in that analysis. Because vitamin D use was not assigned randomly, the investigators used several statistical techniques to reduce the influence of differences between patients. A multivariable time-dependent Cox proportional hazards model adjusted for age and sex and accounted for changes in vitamin D exposure during follow-up. They also used inverse probability of treatment weighting, or IPTW, to create a statistical “pseudo-population” in which the exposed and unexposed groups were more comparable. Propensity scores were calculated from age, sex, white blood cell count, platelet count and hemoglobin level. The researchers then used weighted Cox models, included laboratory measurements as time-varying variables and evaluated potential statistical problems such as multicollinearity and violations of the proportional-hazards assumption. A Mantel–Byar test was applied to address immortal-time bias, which can occur when patients must survive long enough to be classified as exposed.

The apparent survival advantage was notable because the vitamin D users were not, on average, younger or obviously healthier at diagnosis. Their median age was 74.1 years, compared with 71.1 years among nonusers. Despite that difference, the vitamin D group showed a median TFS of 147 months—more than 12 years—while the nonuser group had a median of 82 months, or just under seven years. The statistical association persisted after the investigators attempted to balance measurable differences between the groups. These results represent a validation of earlier work by the same research team, which had linked vitamin D supplementation with longer treatment-free survival and, among younger patients, a longer time to first treatment. The importance of the new analysis lies in its scale and real-world setting: rather than relying on a small clinical experiment or a single laboratory measurement, it follows thousands of patients across routine healthcare records. Even so, the study remains observational. Patients were not randomly assigned to take vitamin D, and the records may not capture every factor that influenced both supplementation and leukemia outcomes.

There are biological reasons why vitamin D might plausibly affect CLL, although the study did not directly test those mechanisms. CLL cells are malignant B lymphocytes, and previous research cited by the investigators has shown that B-CLL cells can express higher levels of the vitamin D receptor than normal B cells. When vitamin D or its active derivatives bind to this receptor, they may influence gene-regulatory pathways involved in cell proliferation, differentiation and survival. Laboratory experiments have reported that pharmacologic vitamin D derivatives can promote apoptosis—the regulated process of cellular self-destruction—through pathways involving caspase 3 and caspase 9. Vitamin D may also influence the tumor microenvironment, the network of immune and support cells surrounding leukemia cells. Deficiency has been proposed to increase the activity of myeloid-derived suppressor cells, immune cells that can dampen antitumor responses and potentially support leukemia growth through regulatory molecules such as microRNA-155. These mechanisms remain hypotheses in the context of patients receiving ordinary supplementation; effects observed with high concentrations of vitamin D derivatives in vitro cannot be assumed to occur at standard clinical doses.

The findings should therefore be interpreted as a signal for further research, not as a recommendation for every person with CLL to begin supplementation. Vitamin D supplements are not risk-free when taken in excessive amounts, and their safety and usefulness depend on a patient’s blood levels, kidney function, calcium balance, medications and other medical conditions. The study also grouped together vitamin D supplements and vitamin D analogs, which may have different biological properties and clinical uses. It did not establish whether supplementation corrected a documented deficiency, whether blood vitamin D concentrations rose consistently, or which dose and formulation might be relevant. In addition, electronic health records can contain incomplete information about adherence, over-the-counter use, diet, sunlight exposure, socioeconomic factors, physical activity and general health. These variables could influence both the likelihood of taking vitamin D and the risk of needing CLL treatment. The fact that vitamin D users were older than nonusers also highlights how complex treatment decisions and health behaviors can be in routine practice, even after statistical adjustment.

The next step is a prospective randomized trial in which people with early-stage CLL are assigned to vitamin D or placebo and followed under standardized conditions. Such a study could determine whether correcting vitamin D deficiency actually slows CLL progression, or whether supplementation merely marks patients who receive different levels of healthcare or have other favorable characteristics. It could also clarify whether the benefit, if real, applies to all patients or only to those with low vitamin D levels, particular genetic features or specific disease-risk profiles. For now, the Israeli cohort offers a striking observation: during a period when physicians have few proven tools to alter the course of early CLL, vitamin D exposure was associated with nearly five additional years of median treatment-free survival. That result is likely to attract attention because it connects a familiar nutritional supplement with one of leukemia’s most important clinical outcomes. But only controlled prospective evidence can determine whether vitamin D is an active ingredient in that association—or simply a marker traveling alongside it.